Caliway Biopharmaceuticals C stock falls 8.54 percent on October 27

Caliway Biopharmaceuticals C stock fell 8.54 percent on October 27, 2026, to TWD 67.50 at 1:30 p.m. CST on the Taiwan Stock Exchange. The next report is scheduled for November 11, 2026, according to Investing.com.

November 11 is the next date

The upcoming release is tied to the period ending September 2026. Investing.com lists forecast revenue of TWD 8.00 million and forecast earnings per share of minus TWD 0.25 for that report, giving investors a concrete benchmark for the next update.

Stock remains near its yearly low

The October 27 price sits TWD 0.?? above the 52-week low of TWD 66.50 and TWD 120.50 below the 52-week high of TWD 188.00. The stock's market capitalization was TWD 105.1 billion, while trading volume reached 11,780,442 shares on October 27, 2026.

Clinical progress meets weak revenue

Caliway is developing CBL-514 for nonsurgical fat reduction and has begun recruitment for a phase 3 trial, according to the company's October 2, 2026 release. The release said phase 2 data showed a 12.01 percent reduction in visceral fat four weeks after the last treatment, compared with a 5.68 percent increase for placebo.

The financial contrast is material. In the second quarter of 2026, revenue was TWD 3.566 million and net loss was TWD 222.516 million, while first-quarter revenue was TWD 0.002 million and net loss was TWD 107.754 million, according to Investing.com. The next report will therefore be read against both the clinical program and the company's limited commercial revenue.

Clinical evidence remains the variable

Caliway Biopharmaceuticals said the first phase 3 results are expected toward the end of 2027. That timetable leaves the November report focused on financial consumption, trial execution and any update on CBL-514 enrollment.

Price and next reporting date

The stock was last at TWD 67.50 on the Taiwan Stock Exchange on October 27, 2026 at 1:30 p.m. CST, down 8.54 percent from the prior close of TWD 73.80. The next scheduled report is November 11, 2026.

Market context: Market report TAIEX.

More news and analyses on Caliway Biopharmaceuticals C stock